The spinout of Leiden University Medical Center is working on a treatment that prevents acute bleeding in patients taking medication for thrombosis.

VarmX, a Netherlands-based biotech spinout from Leiden University Medical Center (LUMC) focusing on the development of therapies in the field of haemostasis and thrombosis, closed a seed round of undisclosed size on Tuesday.

The money was supplied by InnovationQuarter, the economic development agency for the South Holland province, and VC firm BioGeneration Ventures, which secured $75m for its latest fund from the EU-owned European Investment Fund (EIF) and the EIF and Dutch state-backed DVI-II this week.

The company was…